WHWK
Whitehawk Therapeutics, Inc.
OpenVolumeMkt capP/EEPSDiv yield
Day – 52-wk –
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Whitehawk Therapeutics, Inc.
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Last reportshaded = implied▲▼ = realized× = |realized| ÷ implied
No other changes.
No other changes.
No thesis.
Whitehawk Therapeutics, Inc., an oncology therapeutics company that develops technologies to establish tumor biology for cancer treatments. It provides a three-asset antibody-drug conjugate (ADC) portfolio to treat cancer. The company was formerly known as Aadi Bioscience, Inc. and changed its name to Whitehawk Therapeutics, Inc. in March 2025. Whitehawk Therapeutics, Inc. was incorporated in 2007 and is headquartered in Morristown, New Jersey.
Whitehawk Therapeutics, Inc., an oncology therapeutics company that develops technologies to establish tumor biology for cancer treatments. It provides a three-asset antibody-drug conjugate (ADC) portfolio to treat cancer. The company was formerly known as Aadi Bioscience, Inc. and changed its name to Whitehawk Therapeutics, Inc. in March 2025. Whitehawk Therapeutics, Inc. was incorporated in 2007 and is headquartered in Morristown, New Jersey.
Annual filing, covered
10-K parsed · Mar 12 '26
Supply-chain ties, covered
Disclosed · both directions
Fund holders, covered
N-PORT holdings
13F holdings, covered
13F quarter · Jun 30 '26
Management, not covered
Not covered · DEF 14A, 8-K 5.02
Company IR feed, not covered
News via newswires & EDGAR
Products, patents, hiring, not covered
Not covered
Annual filing, covered
10-K parsed · Mar 12 '26
Supply-chain ties, covered
Disclosed · both directions
Fund holders, covered
N-PORT holdings
13F holdings, covered
13F quarter · Jun 30 '26
Management, not covered
Not covered · DEF 14A, 8-K 5.02
Company IR feed, not covered
News via newswires & EDGAR
Products, patents, hiring, not covered
Not covered
Whitehawk Therapeutics, Inc.
3.08
−0.04 · −1.28%
post 3.08 0.00%
Tall tick = annual report · Source: EDGAR
Largest filed tie
—
| Manager | Value | % base | |
|---|---|---|---|
| Yu Fan | $22.3M | 11.24% | +134.85% |
| Acuta Capital Partners | $21.5M | 10.84% | +37.40% |
| QVT Financial | $21.1M | 10.67% | 0.00% |
| Suvretta | $19.7M | 9.94% | +16.22% |
| Orbimed | $18.0M | 9.10% | −5.56% |
| Manager | Value | % base | |
|---|---|---|---|
| Yu Fan | $22.3M | 11.24% | +134.85% |
| Acuta Capital Partners | $21.5M | 10.84% | +37.40% |
| QVT Financial | $21.1M | 10.67% | 0.00% |
| Suvretta | $19.7M | 9.94% | +16.22% |
| Orbimed | $18.0M | 9.10% | −5.56% |
Same SIC code · 6
Same SEC industry code: ELI Lilly & Co, Johnson & Johnson, AbbVie Inc. and 3 more; no measured co-movers for Whitehawk Therapeutics, Inc..
Same SIC code · 6
Same SEC industry code: ELI Lilly & Co, Johnson & Johnson, AbbVie Inc. and 3 more; no measured co-movers for Whitehawk Therapeutics, Inc..
Bull0
—
Bear2
—
—
Expected move
No implied move.